Please login to the form below

The brand strategy revolution

Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need.

Public perception of the pharmaceutical industry has plummeted in the last year. Across the world patients are feeling disconnected and, worse, distrusting of the very brands they rely on to improve or save their lives.

According to Edelman’s Trust Barometer, which includes data from more than 33,000 respondents, trust in healthcare declined across 17 out of 28 markets. While many will place the blame on the rising cost of healthcare, 68% of respondents said they would trust a pharmaceutical, drug or biotech company more if it also provided information, tools and support to help them manage their disease.

Additionally, Manhattan Research 2017 reports 43% of physicians say no pharma company is providing quality digital support for their day-to-day practice. This criticism from two of the industry’s most crucial customers shows that pharma doesn’t just have a trust problem, it doesn’t understand its stakeholders.

"Jenna Earl, Head of Brand Strategy and Leah Carlisle, Consultant are revolutionising pharma’s approach to brand strategy, revealing a new tool for ensuring stakeholder-centricity – ‘The Four Corners of Brand Experience’"

Pharma typically takes a traditional approach to brand strategy, focused on promoting the benefits of the product or service. However, during the last decade, consumer brands have taken a radically different approach – starting their strategic planning by understanding their customers’ needs and focusing on the overall customer experience.

Blue Latitude Health’s original research shows that while 65% of pharma brands consider themselves effective or very effective at incorporating market insights into their strategy, more than 50% do not begin collecting customer insight until 6-8 months prior to launch. However, many brands begin developing their campaigns 9-16 months before launch, illustrating that the creation of the brand starts well before the customer insights have been collected and analysed.

It’s time to make a change, both to prevent global trust from falling further and to ensure pharma’s products and services have the best chance of improving patient outcomes. That’s why Jenna Earl, Head of Brand Strategy and Leah Carlisle, Consultant are revolutionising pharma’s approach to brand strategy, revealing a new tool for ensuring stakeholder-centricity – ‘The Four Corners of Brand Experience’.

DOWNLOAD THE FULL ARTICLE HERE

22nd March 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health